drugset / Trial / NCT02211846

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

NCT02211846

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.

Timeline

Start
2014-09-21
Primary completion
2015-09-21
Completion
2015-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified Oral

Indications